“BRAND"药学服务模式用于驱动基因阳性晚期NSCLC患者的实践研究

打开文本图片集

中图分类号R95 文献标志码A 文章编号 1001-0408（2026）05-0655-05

DOI 10.6039/j.issn.1001-0408.2026.05.18

Practical study on the application of“BRAND”pharmaceutical care model in advanced NSCLC patients withpositive driver genes

YU Jiankang，GONG Wei，SHI Jinfang，TANG Jie，GONG Yinhua（Dept. of Pharmacy，the First Afiliated Hospital of SoochowUniversity，Jiangsu Suzhou 215ooo，China）

ABSTRACTOBJECTIVE To establisha“BRAND”pharmaceutical care model for advanced non-small cell lung cancer （NSCLC）patients withpositivedriver genes，providing theoreticalandpracticalreferences fortheclinicalimplementationof preciseandindividualizedoncologypharmaceuticalcare.METHODsOne hundredpatientsadmitedtothedepartmntof pulmonaryandcriticalcare medicine inour hospital from January2023toMay 2024werecolected meetingtheinclusionand exclusioncriteria.Patientswererandomlydivided intocontrolgroupandinterventiongroup，with5Opatientsineach group.The controlgroupreceivedroutinepharmaceuticalcare，whilethe interventiongroupreceived pharmaceuticalcareunderthe“BRAND" model（colectingpatients’basicinformation，reviewingdiseasetreatment-relatedinformation，conductingprecisemedication assessments，formulatingindividualized pharmaceuticalcareplansforthe nextsteps，andimplementing medication guidanceand follow-upmanagement）.Thestudywasconductedina3-wekcycleforatotalof4cycles.Themedicationcompliance，qualityof life，laboratorytest indicators，incidenceofdrug-relatedadverseeventsandsatisfactionofpatientsinbothgroupswerecompared beforeandaftertheinterventiontoevaluatetheefects.RESULTSAfter12 weeksofintervention，comparedwiththecontrol group，themedicationcompliance，cognitivefunction，socialfunctionandsatisfactionofpatientsintheinterventiongroupwere improved significantly （ .P<0.05 ）；the severity of fatigue and constipation and the incidence of drug-related adverse events were significantly reduced（ ΔP<0.05 ），and there was no statistically significant difference in laboratory test indicators（ P>0.05 ） CONCLUSIONs The“BRAND”pharmaceuticalcare modelcaneffectively improve the medicationcomplianceof patients with advancedNSCLCwith positivedrivergenesandimprovetheirqualityoflife.Thisstudycanprovideafeasiblepathforclinical pharmacists to carry out standardized and high-quality pharmaceutical care.

KEYWORDS“BRAND”pharmaceutical care model；positivedrivergene；advanced stage；non-small cell lungcancer; pharmaceutical service

国际癌症研究机构GLOBOCAN2022数据库（https：//gco.iarc.who.int）的统计结果显示，2022年全球新发肺癌病例数约为248.1万例，死亡病例数为181.7万例，其发病率与死亡率均居全球恶性肿瘤首位；而我国肺癌的新发病例数约为106.1万例，死亡病例数为73.3万例[-2]。（剩余7759字）